These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25854145)

  • 1. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
    Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
    Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
    Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
    Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
    Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
    PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
    Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
    Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
    Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
    Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome deubiquitinases as novel targets for cancer therapy.
    D'Arcy P; Linder S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
    Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
    Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
    Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
    Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
    Wang X; Stafford W; Mazurkiewicz M; Fryknäs M; Brjnic S; Zhang X; Gullbo J; Larsson R; Arnér ES; D'Arcy P; Linder S
    Mol Pharmacol; 2014 Jun; 85(6):932-45. PubMed ID: 24714215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
    Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
    Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
    Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
    Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
    Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
    Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
    Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
    Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deubiquitinase inhibition as a cancer therapeutic strategy.
    D'Arcy P; Wang X; Linder S
    Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
    Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
    Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
    Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
    Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
    Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
    Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
    Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
    Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.
    Zhou B; Zuo Y; Li B; Wang H; Liu H; Wang X; Qiu X; Hu Y; Wen S; Du J; Bu X
    Mol Cancer Ther; 2013 Aug; 12(8):1381-92. PubMed ID: 23696216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.